Neuropathic pain is the sensation of pain due to abnormal discharges of impaired or injured neural structures in the peripheral &/or central nervous system.
It is characterized by hyperesthesia, hyperalgesia and allodynia.
Common neuropathic pain syndromes are central neuropathic pain, painful diabetic peripheral neuropathy, postherpetic neuralgia, trigeminal neuralgia, postsurgical neuropathic pain, HIV-related neuropathy, lumbosacral radiculopathy and complex regional pain syndrome.
New drug applications approved by US FDA as of 1 - 15 October 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Capsaicin 8% patch shows potential as a long-term treatment option for non-diabetic patients with peripheral neuropathic pain, with a new study reporting that repeat treatment over 52 weeks is well tolerated, producing sustained reductions in average pain intensity with variable sensory function alteration and minimal chance of complete sensory loss.
Duloxetine demonstrates long-term safety and efficacy in the treatment of Japanese patients with diabetic neuropathic pain, as observed in a 52-week, randomised, open-label extension of a 12-week, double-blind, placebo-controlled study.
New drug applications approved by US FDA as of 1 - 15 Oct 2015 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.
Topical menthol may be a new analgaesic for cancer treatment-associated neuropathic pain caused by chemotherapy-induced peripheral neuropathy or surgical scars, as presented in a proof of concept study.
Liposomal topical capsaicin exhibits safety and good tolerability in patients with post herpetic neuralgia who continued to be symptomatic after first- and second-line treatment, based on a pilot study.
Ginkgo biloba has been shown to improve cognitive as well as neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) and mixed dementia. During a Schwabe-sponsored symposium last 20 October 2014 held at the University of Malaya in Malaysia, Professor Serge Gauthier of the McGill Centre for Studies in Aging in Quebec, Canada, and Dr Robert Hoerr of the Dr Willmar Schwabe GmbH & Co. KG in Germany, discussed studies that support the safety and efficacy of Ginkgo biloba extract (EGb 761®) in patients with AD and dementia.